Titlebook: Rare Tumors of the Thyroid Gland; Diagnosis and WHO cl José Manuel Cameselle-Teijeiro,Catarina Eloy,Manue Book 2018 Springer International

Geyser

Therapeutic Options,sociated with a guarded prognosis, namely, with increased recurrence rate and disease-specific mortality. Nonetheless, the small number of cases precludes the design of clinical trials to assess if a specific therapeutic strategy is valuable for those patients. The clinical challenge increases when

潛移默化

Book 2018logical and immunohistochemical aspects. Whenever necessary, namely for differential diagnosis and/or therapy purposes, molecular data are also highlighted. In order to understand the histogenesis of rare lesions and to be able to make a differential diagnosis, the editors use the WHO book for endoc

運(yùn)動(dòng)吧

nderstanding of thyroid oncology through the study of rare l.This book documents the most important clinicopathological features of rare thyroid tumours with an emphasis (and ample documentation) on their histological and immunohistochemical aspects. Whenever necessary, namely for differential diagn

THROB

Introduction,We think this is the right time to publish a book on rare tumours of the thyroid gland for a number of reasons.

推測

Rare Familial Tumours,Approximately 3–9% of non-medullary thyroid carcinomas occur on a familial basis [1]. About 5% of these tumours are syndromic, whereas the remaining 95% of all cases of familial non-medullary thyroid carcinomas (FNMTCs) are non-syndromic with less well-defined genetic susceptibility [1].

品牌

DUCE

978-3-319-87021-2Springer International Publishing AG 2018

凹槽

http://image.papertrans.cn/r/image/821276.jpg

蔓藤圖飾

https://doi.org/10.1007/978-3-319-61182-2Papillary Carcinoma; Follicular Carcinoma; Hürthle cells; Hodgkin; Medullary Carcinoma

paleolithic